Although there are challenges for targeting ADGRG6, small molecule modulators have potential for therapeutic use against many ADGRG6‐disease linked conditions, including cancers where ADGRG6 overexpression may contribute to the disease (see Section 3). This evidence concerns the gene ADGRG6 and cancer.